Work

Abstract LB-014: Antibody targeting soluble NKG2D ligand sMIC sensitizes metastatic prostate tumor and other MIC+tumors to PD1/PD-L1 blockade therapy in pre-clinical models

Cites:
Cited by: 1
Related to: 10